Navigation Links
American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD
Date:5/16/2008

Endorsed by the American Academy of Child and Adolescent Psychiatry, the American College of Cardiology, Children and Adults with Attention-Deficit/Hyperactivity Disorder and the National Initiative for Children's Healthcare Quality

DALLAS, May 16 /PRNewswire-USNewswire/ -- The American Heart Association released on April 21, 2008 a statement about cardiovascular evaluation and monitoring of children receiving drugs for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As a result of language in the news release and the statement as published, there have been conflicting interpretations of the recommendations regarding the use of an electrocardiogram (ECG) in assessing children with ADHD who may need treatment with medications. The purpose of this joint advisory of the American Academy of Pediatrics (AAP) and the American Heart Association (AHA) is to clarify the recommendations.

-- The scientific statement included a review of data that show children

with heart conditions have a higher incidence of ADHD.

-- Because certain heart conditions in children may be difficult (even, in

some cases, impossible) to detect, the AAP and AHA feel that it is

prudent to carefully assess children for heart conditions who need to

receive treatment with drugs for ADHD.

-- Obtaining a patient and family health history and doing a physical exam

focused on cardiovascular disease risk factors (Class I recommendations

in the statement) are recommended by the AAP and AHA for assessing

patients before treatment with drugs for ADHD.

-- Acquiring an ECG is a Class IIa recommendation. This means that it is

reasonable for a physician to consider obtaining an ECG as part of the

evaluation of children being considered for stimulant drug therapy, but

this should be at the physician's judgment, and it is not mandatory

to obtain one.

-- Treatment of a patient with ADHD should not be withheld because an ECG

is not done. The child's physician is the best person to make the

assessment about whether there is a need for an ECG.

-- Medications that treat ADHD have not been shown to cause heart

conditions nor have they been demonstrated to cause sudden cardiac

death. However, some of these medications can increase or decrease

heart rate and blood pressure. While these side effects are not usually

considered dangerous, they should be monitored in children with heart

conditions as the physician feels necessary.

An erratum to the statement has been developed to clarify the language and to assure that the intent is clear to all readers. This is available at:

http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.107.189473/ DC1.

This clarification has been endorsed by the American Academy of Child and Adolescent Psychiatry, the American College of Cardiology, Children and Adults with Attention-Deficit/Hyperactivity Disorder and the National Initiative for Children's Healthcare Quality.


'/>"/>
SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting
2. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
3. Statement from Larry Minnix, President & CEO American Association of Homes and Services for the Aging, On the Government Accountability Offices (GAO) Nursing Home Oversight Report
4. American Red Cross Vindicated in J&J Lawsuit
5. The American Red Cross Commits $10 Million to Assist China Earthquake Survivors
6. Americans must consider cost and effectiveness when comparing and choosing medical interventions
7. American Red Cross Supports China and Myanmar Relief Efforts
8. American Diabetes Wholesale Launches Affiliate Program
9. The American College of Cardiology, American Heart Association and the Heart Rhythm Society Release Updated Cardiac Device-Based Therapy Guidelines
10. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
11. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: